26.42
price up icon6.49%   1.61
 
loading
Schlusskurs vom Vortag:
$24.81
Offen:
$24.9
24-Stunden-Volumen:
3.68M
Relative Volume:
2.08
Marktkapitalisierung:
$4.63B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-382.71M
KGV:
-10.08
EPS:
-2.62
Netto-Cashflow:
$-325.64M
1W Leistung:
+15.67%
1M Leistung:
+12.71%
6M Leistung:
+65.75%
1J Leistung:
-4.24%
1-Tages-Spanne:
Value
$24.46
$26.50
1-Wochen-Bereich:
Value
$22.33
$27.06
52-Wochen-Spanne:
Value
$12.72
$28.08

Immunovant Inc Stock (IMVT) Company Profile

Name
Firmenname
Immunovant Inc
Name
Telefon
917-580-3099
Name
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Name
Mitarbeiter
362
Name
Twitter
Name
Nächster Verdiensttermin
2025-08-08
Name
Neueste SEC-Einreichungen
Name
IMVT's Discussions on Twitter

Vergleichen Sie IMVT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IMVT
Immunovant Inc
26.42 4.35B 0 -382.71M -325.64M -2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.04 113.14B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
741.29 78.49B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
877.94 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
397.55 54.51B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
197.01 41.64B 447.02M -1.18B -906.14M -6.1812

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-14 Eingeleitet Truist Hold
2025-07-10 Fortgesetzt Goldman Neutral
2025-03-03 Eingeleitet Jefferies Hold
2025-01-03 Herabstufung Wolfe Research Outperform → Peer Perform
2024-10-10 Fortgesetzt Raymond James Outperform
2024-10-09 Bestätigt Oppenheimer Outperform
2024-03-28 Eingeleitet Oppenheimer Outperform
2024-03-13 Eingeleitet Goldman Buy
2024-02-20 Eingeleitet JP Morgan Overweight
2024-02-15 Eingeleitet Wolfe Research Outperform
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-10-13 Hochstufung UBS Neutral → Buy
2023-09-26 Hochstufung Raymond James Mkt Perform → Outperform
2023-05-01 Eingeleitet BofA Securities Buy
2023-04-25 Eingeleitet Citigroup Buy
2023-03-31 Eingeleitet Piper Sandler Overweight
2023-03-30 Eingeleitet Stifel Buy
2023-02-15 Eingeleitet Cantor Fitzgerald Overweight
2023-02-13 Hochstufung Guggenheim Neutral → Buy
2023-01-03 Hochstufung Wells Fargo Equal Weight → Overweight
2022-09-26 Herabstufung UBS Buy → Neutral
2021-12-08 Eingeleitet Wells Fargo Equal Weight
2021-08-03 Herabstufung Robert W. Baird Outperform → Neutral
2021-08-02 Herabstufung Credit Suisse Neutral → Underperform
2021-06-01 Herabstufung Guggenheim Buy → Neutral
2021-06-01 Herabstufung Stifel Buy → Hold
2020-10-28 Eingeleitet UBS Buy
2020-10-12 Eingeleitet Guggenheim Buy
2020-10-08 Eingeleitet Stifel Buy
2020-10-02 Eingeleitet Credit Suisse Outperform
2020-08-26 Bestätigt H.C. Wainwright Buy
2020-08-25 Eingeleitet Raymond James Outperform
2020-07-29 Eingeleitet H.C. Wainwright Buy
2020-02-24 Eingeleitet SVB Leerink Outperform
Alle ansehen

Immunovant Inc Aktie (IMVT) Neueste Nachrichten

pulisher
Dec 13, 2025

EPS Watch: Why OrthoPediatrics Corp. stock appeals to dividend seekersWeekly Stock Report & Low Drawdown Trading Strategies - moha.gov.vn

Dec 13, 2025
pulisher
Dec 12, 2025

Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - Investing.com

Dec 12, 2025
pulisher
Dec 12, 2025

Immunovant Raises $550 Million Through Stock Offering - TipRanks

Dec 12, 2025
pulisher
Dec 12, 2025

Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement - Seeking Alpha

Dec 12, 2025
pulisher
Dec 12, 2025

Immunovant Enters Underwriting Agreement for Stock Offering - TradingView — Track All Markets

Dec 12, 2025
pulisher
Dec 12, 2025

Immunovant (NASDAQ:IMVT) Stock Price Up 8.1%Here's Why - MarketBeat

Dec 12, 2025
pulisher
Dec 12, 2025

Immunovant, Inc. $IMVT is Armistice Capital LLC's 9th Largest Position - MarketBeat

Dec 12, 2025
pulisher
Dec 12, 2025

Immunovant drops 7%, prices $550M stock offering - MSN

Dec 12, 2025
pulisher
Dec 11, 2025

Immunovant announces $550 million stock offering - MSN

Dec 11, 2025
pulisher
Dec 11, 2025

Latham & Watkins Advises on Immunovant’s US$550 Million Offering of Common Stock - Latham & Watkins LLP

Dec 11, 2025
pulisher
Dec 11, 2025

Immunovant announces $550 million stock offering and clinical program updates - Investing.com Canada

Dec 11, 2025
pulisher
Dec 11, 2025

HighVista Strategies LLC Buys 87,160 Shares of Immunovant, Inc. $IMVT - MarketBeat

Dec 11, 2025
pulisher
Dec 11, 2025

Immunovant announces $550 million stock offering and clinical program updates By Investing.com - Investing.com South Africa

Dec 11, 2025
pulisher
Dec 11, 2025

Immunovant Announces $550 Million Stock Offering - TipRanks

Dec 11, 2025
pulisher
Dec 11, 2025

Immunovant announces pricing of $550 million common stock financing - marketscreener.com

Dec 11, 2025
pulisher
Dec 11, 2025

Immunovant Announces Pricing Of $550 Million Common Stock Financing - TradingView — Track All Markets

Dec 11, 2025
pulisher
Dec 11, 2025

Immunovant Prices $550 Million Stock Offering - marketscreener.com

Dec 11, 2025
pulisher
Dec 11, 2025

Immunovant Announces Pricing of $550 Million Common Stock Financing - The Globe and Mail

Dec 11, 2025
pulisher
Dec 11, 2025

Immunovant (Nasdaq: IMVT) raises $550M to support potential IMVT-1402 Graves’ launch - Stock Titan

Dec 11, 2025
pulisher
Dec 10, 2025

Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Dec 10, 2025
pulisher
Dec 10, 2025

Norges Bank Buys Shares of 687,662 Immunovant, Inc. $IMVT - MarketBeat

Dec 10, 2025
pulisher
Dec 06, 2025

55,524 Shares in Immunovant, Inc. $IMVT Purchased by Capital Fund Management S.A. - MarketBeat

Dec 06, 2025
pulisher
Dec 05, 2025

Two Seas Capital LP Boosts Stake in Immunovant, Inc. $IMVT - MarketBeat

Dec 05, 2025
pulisher
Dec 04, 2025

Insider Selling: Immunovant (NASDAQ:IMVT) Director Sells 15,000 Shares of Stock - MarketBeat

Dec 04, 2025
pulisher
Dec 04, 2025

Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 04, 2025
pulisher
Dec 04, 2025

Insider Selling: Immunovant (NASDAQ:IMVT) Director Sells 22,249 Shares of Stock - MarketBeat

Dec 04, 2025
pulisher
Dec 03, 2025

Immunovant Executives Sell Shares Under Trading Plans - TradingView

Dec 03, 2025
pulisher
Dec 03, 2025

Dir Fromkin Surrenders 22,249 Of Immunovant Inc [IMVT] - TradingView

Dec 03, 2025
pulisher
Dec 02, 2025

Is Immunovant (IMVT) Overvalued? Taking Stock of Its Premium Price-to-Book Multiple - Yahoo Finance

Dec 02, 2025
pulisher
Dec 01, 2025

Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings - MSN

Dec 01, 2025
pulisher
Dec 01, 2025

Immunovant (IMVT) Stock Analysis Report | Financials & Insights - Benzinga

Dec 01, 2025
pulisher
Nov 30, 2025

XTX Topco Ltd Buys New Holdings in Immunovant, Inc. $IMVT - MarketBeat

Nov 30, 2025
pulisher
Nov 29, 2025

Tejara Capital Ltd Raises Position in Immunovant, Inc. $IMVT - MarketBeat

Nov 29, 2025
pulisher
Nov 29, 2025

Immunovant, Inc. $IMVT Shares Acquired by Geode Capital Management LLC - MarketBeat

Nov 29, 2025
pulisher
Nov 29, 2025

(IMVT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com

Nov 29, 2025
pulisher
Nov 28, 2025

12 Best Short Squeeze Stocks to Buy Right Now - Insider Monkey

Nov 28, 2025
pulisher
Nov 26, 2025

Immunovant’s Earnings Call Highlights Clinical Success and Financial Strength - MSN

Nov 26, 2025
pulisher
Nov 26, 2025

Officer Geffner Files To Sell 50,000 Of Immunovant Inc [IMVT] - TradingView

Nov 26, 2025
pulisher
Nov 26, 2025

Officer Geffner Files To Sell 103,897 Of Immunovant Inc [IMVT] - TradingView

Nov 26, 2025
pulisher
Nov 25, 2025

Immunovant (IMVT): Assessing Valuation Following R&D Leadership Restructuring and CMO Departure - Sahm

Nov 25, 2025
pulisher
Nov 24, 2025

JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 - MSN

Nov 24, 2025
pulisher
Nov 23, 2025

Have Insiders Sold Immunovant Shares Recently? - simplywall.st

Nov 23, 2025
pulisher
Nov 22, 2025

Immunovant Restructures R&D Leadership with CMO Departure - The Globe and Mail

Nov 22, 2025
pulisher
Nov 22, 2025

Immunovant COO Gloria sells $298k in shares By Investing.com - Investing.com Nigeria

Nov 22, 2025
pulisher
Nov 21, 2025

Immunovant COO Gloria sells $298k in shares - Investing.com

Nov 21, 2025
pulisher
Nov 21, 2025

Immunovant Insider Sold Shares Worth $298,237, According to a Recent SEC Filing - MarketScreener

Nov 21, 2025
pulisher
Nov 21, 2025

Immunovant COO Gloria Melanie Sells Shares to Cover Tax Obligations - TradingView

Nov 21, 2025
pulisher
Nov 21, 2025

[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan

Nov 21, 2025
pulisher
Nov 21, 2025

[8-K] Immunovant, Inc. Reports Material Event | IMVT SEC FilingForm 8-K - Stock Titan

Nov 21, 2025
pulisher
Nov 21, 2025

Immunovant, Inc. Announces Cessation of Michael Geffner, M.D., M.B.A. as Chief Medical Officer, Effective November 21, 2025 - marketscreener.com

Nov 21, 2025
pulisher
Nov 19, 2025

How analysts rate Immunovant Inc. stock todayInsider Selling & Technical Entry and Exit Tips - newser.com

Nov 19, 2025

Finanzdaten der Immunovant Inc-Aktie (IMVT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$38.39
price down icon 1.08%
$95.41
price down icon 0.72%
$31.31
price down icon 3.07%
$94.81
price down icon 1.24%
biotechnology ONC
$319.06
price down icon 0.55%
$197.01
price up icon 0.91%
Kapitalisierung:     |  Volumen (24h):